Therapeutic agent

Intravenous Immunoglobulin (IVIG)

Also known as: Intravenous Immunoglobulin (IVIG)

ModerateEvidence level
2Registered trials
6Conditions
3Study references

Evidence Summary

Evidence Level
Moderate
Mechanism
Anti-inflammatory, Enrollment: Actual, Immunomodulatory, Neurological / Autonomic
Safety
Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing
See linked studies/trials for reported doses and durations; typical protocols vary widely.
Investigational for listed conditions. 2 associated trial(s) and 5 study reference(s) in current data. Review primary sources and consult specialists before use.

Clinical Trials

2 trial(s) registered

NCT IDTitlePhaseStatus
NCT06305780RECOVER-AUTONOMIC Platform ProtocolPhase 2Completed
NCT06305793RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)Phase 2Completed

Key Studies / References